PUBLIC PORTAL

MEDICALLY REVIEWED

Romosozumab (Evenity) for the Treatment of Osteoporosis

Share on email
Share on print
Share on whatsapp

In May 2021, the Health Sciences Authority (HSA) approved the use of Romosozumab (Evenity), a novel biologic, for the treatment osteoporosis in postmenopausal women at high risk of fractures. Fragility fractures are common amongst postmenopausal . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading

diet

Diet & Nutrition

In May 2021, the Health Sciences Authority (HSA) approved the use of Romosozumab (Evenity), a novel biologic, for the treatment osteoporosis in postmenopausal women at

Read More »